Novartis Investigative Site

Exeter EX2 5DW

0 studies enrolling now · 12 studies all time

What they study most

Atherosclerosis, Atherosclerotic Cardiovascular Disease, Breast Cancer, Chronic Heart Failure With Reduced Ejection Fraction, Diabetes Mellitus, Diabetes Type 1, Familial Hypercholesterolemia, Heart Failure With Reduced Ejection Fraction, Hidradenitis Suppurativa, Leukaemia, Lymphocytic, Chronic, Melanoma, Myelodysplastic Syndromes

Studies at this site

• Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). — Completed
• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D — Completed
• This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). — Completed
• Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC — Completed
• An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol — Completed
• Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study — Completed
• A Study to Evaluate the Change in Weight After 24 Weeks Treatment With LIK066 in Obese or Overweight Adults — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia — Stopped early
• Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early
• ACZ885 in Type 1 Diabetes Mellitus — Withdrawn before enrolling